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a b s t r a c t
Argemone mexicana (AM), a validated herbal medicine for uncomplicated malaria, seems to
prevent severe malaria without completely clearing parasites in most patients. This study,
in a high transmission area of South Mali, explores whether residual parasitaemia at day
28 was associated with subsequent malaria episodes and/or anaemia.
Three hundred and one patients were randomly assigned to AM or arte-
sunate/amodiaquine as ﬁrst line treatment, of whom 294 were followed up beyond the
standard 28 days, to 84 days. From day 29 to day 84, there were no signiﬁcant differences
between treatment groups in new clinical episodes of uncomplicated malaria (0.33 vs 0.31
episodes/patient), severe malaria (<6% per month of patients aged ≤5 years) or moderate
anaemia (hematocrit <24%: 1.1% in both groups at day 84). Total parasite clearance at day
28 was not correlated with incidence of uncomplicated or severe malaria or of moderate
anaemia over the subsequent two months.Total parasite clearance at day28wasnot clinically important in the context of high trans-
mission. If this ﬁnding can be conﬁrmed, some antimalarials which are clinically effective
but do not completely clear parasites could nevertheless be appropriate in high trans-
mission areas. Such a policy could be tested as a way to delay resistance to artemisinin
pies.
yal Soccombination thera
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. IntroductionMalaria is one of the principle causes of mortality in
frican children, and one of the main causes of morbid-
ty in tropical countries. Although effective treatments
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exist, their widespread use for the home-based manage-
ment of malaria (HMM) would favour the spread of drug
resistance.1 Many populations in remote areas rely on local
traditional herbal remedies for the ﬁrst-line treatment of
malaria.2
Local communities in Mali use herbal preparations as
the ﬁrst treatment for more than 80% of malaria episodes.3
Argemone mexicana (AM) decoction was selected as the
most promising from 160 traditional recipes.3–5 This
ygiene. Published by Elsevier Ltd. All rights reserved.
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plant is all the more interesting because it is widespread
throughout the tropics (including Latin America and Asia).
After completion of toxicological studies, a dose-escalating
clinical study showed a dose response, no serious adverse
events and a sharp decline in parasitaemia (from a geo-
metric mean of 14859 at day 0 to a geometric mean of 174
parasites permcl at day 4) although generallywithout total
parasite clearance.6
Two strategies for HMM were compared in a ran-
domised controlled trial (RCT): AM as ﬁrst line treatment
with artesunate/amodiaquine (As/Aq) as second line
(‘AM group’); or the standard As/Aq as ﬁrst line with
another artemisinin combination therapy (ACT), artheme-
ter/lumefantrine, as second line (‘ACT group’).7 Following
the usual practice of assessing antimalarial treatments by
outcome in the 28 days after diagnosis, we found that
progress to severe malaria was 1.9% in children aged ≤5
years in both groups, and 0% among those aged >5years
old, so that the incidence of severe malaria was kept to a
lower level than reported in comparable studies of HMM.8
However the AM and ACT groups were very different in
termsof parasite clearance. Theproportion of patientswith
parasitaemia at day 28 was 63–76% in the AM group and
21–49% in the ACT group (lower and upper estimates, P <
0.001 with both estimates).
There has been some debate on the clinical signiﬁcance
of total parasite clearance, especially in areas of high trans-
mission. WHO regards parasite clearance at 28 days as the
gold standard for evaluating drug efﬁcacy.9 After parasite
clearance in asymptomatic patients, the incidence of clin-
ical malaria episodes was reduced for 56 days, but then
increased from days 56–112.10 This suggests that patients
are re-infected within a few weeks.
As our hypothesis was that the AM and ACT treatment
strategies could be clinically equivalent (hence a ‘non-
inferiority trial’ design) but differ in parasite clearance at
28 days, we decided to follow up the patients in the RCT for
an extended period of 84 days, in order to detect potential
differences between the two groups after the conventional
28 day study. In order to produce results useful for pol-
icy makers, we focused on outcome measures of public
health importance: incidence of uncomplicated and severe
malaria episodes; prevalence of anaemia; serious adverse
events; re-treatments with the second-line antimalarial
andcost.Malianmedical andpublichealthauthoritieswere
interested in a real situation estimate (at least ‘as real as
possible’), the primary aim being to study a new ‘médica-
ment traditionnel amélioré’ (Improved Traditional Drug),
with a reasonable estimate of the effects to be anticipated
when used outside of clinical settings.
2. Methods
2.1. Participants
This study was conducted in the remote village of Mis-
sidougou, in the south-east of Mali. Patients of all ages
ﬁrst consulted the village health worker, who referred to
the study team all patients whom he presumed to have
malaria (mainly on the basis of a history of fever). Pregnant
womenwere included sinceAMdecoction is regularly usedropical Medicine and Hygiene 105 (2011) 23–31
by pregnant women, and animal studies showed no evi-
dence of reproductive toxicity. We included all consenting
patients considered as having malaria by the village health
worker (in order to reﬂect the real ﬁeld situation of public
health programmes), with a history of fever in the last day,
except those with signs of severe malaria, those who had
already ingested a full dose of antimalarials on the same
day, and those unable to return for follow-up.
2.2. Treatment interventions
The treatment interventions, randomisation and
follow-up in the ﬁrst 28 days have been described
elsewhere.7 In summary, sample size was computed in
order to detect a difference of 15% assuming an adequate
clinical response rate of at least 85% with an ACT ( =
0.05, 1- = 0.80, two-tailed test). Patients were randomly
assigned to two groups, AM or ACT, using a computer-
generated random number table and a 2:1 randomisation
ratio with blocks of six stratiﬁed for age (<1 year, 1–5
years, >5 years). Due to the very different nature of the
two treatments, it was not possible to blind the patients or
the clinicians to the treatments being taken. However the
treatment groups were not known to the microscopists
when performing parasite counts.
The ﬁrst-line treatment (detailed below) was used for
the initial illness, and during the follow-up period for
any new febrile episode in a patient who had previously
improved more than 14 days after the start of the previ-
ous treatment. Blood ﬁlms were taken before the start of
treatment but were analysed later. The second-line treat-
ment was used only if the ﬁrst-line treatment failed or if
there were signs of severity. In both groups intramuscular
artemether was used if the patient was unable to swallow.
If therewere signs of another infection (for example a chest
infection) this was also treated.
AM Group: AM aerial parts were harvested and dried.
For each new treatment, patients (or their parents) were
given a bag of 500g of the dried plant material, and were
told how to prepare the decoction. Patientswere advised to
take this treatment for one to two weeks. The second-line
treatment was oral As/Aq.
ACT Group: Patients were given artesunate and
amodiaquine tablets in a co-blister pack (Arsucam®,
Sanoﬁ-synthelabo), according to theirweight, in thedosage
schedule given on the pack insert. Women who were
known to be pregnant were treated with sulphadoxine-
pyrimethamine (SP), three tablets in a single dose,
instead of As/Aq. The second-line treatment was oral
artemether/lumefantrine (Coartem®, Novartis).
2.3. Outcomes
The primary outcome measure for comparison over
the 84-day follow-up was incidence of new episodes of
uncomplicated malaria (fever reported in the last 24hours,
irrespective of other infections, conﬁrmed on thick ﬁlm).
Secondary outcome measures were incidence of severe
malaria from days 29 to 84, prevalence of moderate
anaemia (haematocrit <24%) at day84, incidenceof adverse
events after day 28 (including follow-up of the babies
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f women pregnant at the time of treatment), need for
etreatment, and cost per patient over the 84 days of
ollow-up. Cost was calculated on the basis of wholesale
osts of medications in Mali at the time of the study, and
ospital bills for any referred patients. The herbalmedicine
ad no monetary cost as it was harvested and prepared
ocally. In the cost analysis, we included all treatment costs
elating to episodes of presumed malaria (cost of drugs,
ncillary treatments, and hospital admission). We did not
nclude opportunity costs of the patients’ and their fami-
ies’ time as this would have been difﬁcult to estimate in a
ommunity of subsistence farmers where most people do
ot receive a salary.
.4. Follow-up
Patients were followed up on days 56 and 84, and were
dvised to return at any time if they experienced a dete-
ioration of their condition, or recurrence of symptoms.
atients who did not return for follow-up were visited at
ome. Thin and thick blood ﬁlms were taken at baseline
nd every follow-up visit. Haematocrit was taken at base-
ine, ondays 28, 56 and84, and in cases of treatment failure.
follow-up visit was made seven months after the start of
he trial to all women pregnant during the study, and a
tandard screening examination was performed to look for
ny abnormalities in their babies.
Laboratory methods are described in detail elsewhere.7
ll blood ﬁlms taken on d 0, d 7, d 28 and the day of a pre-
umed new episode of malaria were read independently
y two microscopists. Parasites were counted per 200 leu-
ocytes (and per 500 leucocytes if there were fewer than
0 parasites per 200 leucocytes). For the purpose of calcu-
ating parasitaemia the leucocyte count was assumed to
e 7.5x109/mcl. A slide was not declared negative until
00 high power ﬁelds had been examined. A sample of
iscordant slides was read by a third microscopist. All
hree microscopists were experienced so discordant pos-
tive/negative results were explored through sensitivity
nalysis rather than assuming that one microscopist was
onsistently ‘correct’. The parasitaemia threshold for con-
rming a new episode of malaria was set at ≥100 per
icrolitre because very low parasitaemia was deemed
nlikely to cause febrile illness in a semi-immune popu-
ation, and because at very low parasitaemia there were
ften discrepancies between microscopists as to the pres-
nce or absence of parasites. Total parasite clearance was
eﬁnedasnoparasites seenbyeithermicroscopist.Haema-
ocrit was measured using microhaematocrit tubes in a
entrifuge. Some haematocrit values are missing because
ome of the capillary tubes burst open in the centrifuge.
.5. Statistical analysis
Results were analysed by intention to treat. Patients
ere only excluded in the course of the study if they
ithdrew consent or if they took a course of antimalar-
al medication which had not been prescribed by the study
eam.Datawere entered andanalysedusingEpi-info6 soft-
are (CDC, Atlanta, GA, USA), with 2 and Fisher’s exact
ests for discrete variables, and Kruskall-Wallis test foropical Medicine and Hygiene 105 (2011) 23–31 25
means. We stratiﬁed by age group (<1, 1–5, >5) for the
analysis of the association between parasite clearance at
day 28 and the incidence of recurrent malaria. We used
logistic regression (SPSS version 16.0, SPSS Inc., Chicago,
IL, USA) to adjust for the effect of multiple variables: age,
sex, temperature at day 28, parasite count at day 28, and
haematocrit at day28.As thedistributionof parasite counts
was skewed we used the following categories of parasite
counts: 0, 1–99, 100–1999, 2000–15000, and >15 000.
2.6. Ethical issues
Patients were only included if they (or in the case of
children, their parents) gave written informed consent.
Patients were followed closely, and were given alternative
treatment if necessary. All treatments were provided free
of charge, including referral to hospital when necessary.
3. Results
3.1. Patients included
Recruitment took place from 29 July to 8 September
2006. Three hundred and one patients were included, and
participant ﬂow is summarised in Figure 1.
3.2. Baseline characteristics
Baseline characteristics are summarised in Table 1. Of
those with a positive blood ﬁlm, only six (2%) did not have
a pure Plasmodium falciparum infection.
3.3. Compliance
All patients in the AM group reported that they drank
the decoction and only 5 patients did not wash with it; 88
patients took the treatment for more than 7 days, although
only 47 of these had been advised to do so by the study
team. Only 4 (2%) took less than the recommended dose. In
contrast 97% of patients in the ACT group reported compli-
ancewith the treatment (the two caseswhodid not comply
with instructions took a double dose on day 0).
3.4. Outcomes at day 28
The outcomes at 28 days were reported in detail
elsewhere.7 In summary, incidence of severe malaria was
under 2.5% in both groups. Most of these cases involved
severe anaemia. There were no cases of coma or con-
vulsions, and no deaths. Clinical cure rates (deﬁned as
clearance of fever and other malaria symptoms by day 14)
were similar. Six percent of the AMgroup and 5% of the ACT
group had to be retreated with the second-line antimalar-
ial by day 14. A new episode of malaria occurred in 16% of
the AM group and 11% of the ACT group between days 15
and 28. The incidence of adverse eventswas similar in both
groups (14% and 19%), and no serious adverse events were
observed.
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Assessed for eligibility: 313 
(patients who consulted healer 
with symptoms of malaria) 
Randomised: 301 
Allocated to AM: 199 
Received AM: 199 Allocated to ACT: 102 
Received ACT: 102 
Parasite +: 88 
Parasite + at d 28: 83 
New clinical episodes, d 29–84: 27 
Lost to follow-up: 0 
Took alternative treatment: 3 
Withdrew consent at d 7: 1 
Parasite + at d 28: 51 
New clinical episodes, d 29–84: 29 
Lost to follow-up: 0 
Took alternative treatment at d 0: 1 
Excluded: 12 
- Exclusion criteria: 10 
- Did not consent: 2 
Took AM for ≤7 d: 111 
Parasite +: 97 
Took AM for >7 d: 88 
Parasite +: 77 
Parasite + at d 28: 70 
New clinical episodes, d 29–84: 37 
Lost to follow-up: 0 
Took alternative treatment: 2 
sed: 86
ana decAnalysed: 107 Analy
Figure 1. Flowchart of patients. (AM = Argemone mexic
3.5. Outcomes at day 84 (Table 2)
At day 84, seven patients were excluded, one who had
withdrawn consent at day 7 and sixwho had taken an anti-
malarial fromanother source (whichmayhave affected the
outcomes).3.6. Incidence of uncomplicated malaria, days 29–84
There were 102 episodes treated presumptively as
new uncomplicated malaria in the AM group (0.53 per
patient) and 50 in the ACT group (0.50 per patient, P=0.65).
Table 1
Baseline characteristics of included patients.
Group
Males, n (%)
Median age, years (IQR)
Mean temperature, ◦C (SD)
Thick ﬁlm positive, n (%)
Geometric mean parasite count in patients with positive thick ﬁlm (per mcl)
Haematocrit, % (SD) [n tested]
AM: Argemone mexicana group; ACT: Artemisinin Combination Therapy group.Analysed: 101  
oction as ﬁrst-line; ACT = artesunate/amodiaquine as ﬁrst line).
On the day of these new episodes, blood ﬁlms were
taken in 97 and 50 in the AM and ACT groups respec-
tively. Of those who had blood ﬁlms taken, uncomplicated
malaria was conﬁrmed with parasitaemia ≥100/mcl in 63
(0.33 per patient) and 31 (0.31 per patient) in the AM
and ACT groups respectively (P=0.76). Of these, seven
episodes were treated presumptively as severe malaria
although subsequent analysis conﬁrmed that they fulﬁlled
the criteria for uncomplicated malaria. Within the AM
group, subgroup analysis showed that the number of new
episodes was signiﬁcantly greater in the patients who had
taken the decoction for more than seven days (0.435 per
AM (n=193) ACT (n = 101)
94 (48.7) 43 (42.6)
5 (2–20) 5 (2–20)
37.0 (1.3) 37.1 (1.4)
171 (88.6) 87 (86.1)
908 975
34.3 (6.0) [153] 34.8 (6.0) [72]
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Table 2
Outcome measures over months 2 and 3 (days 29 to 84) according to treatment group [95% CI].
Treatment group AM (n=193) ACT (n=101) P-value
0.33 [0.26–0.40] 0.31 [0.22–0.41] 0.35
5/102 (4.9%) [1.6–11.1] 1/52 (1.9%) [0.05–10.3] 0.37
2 (1.1) 1 (1.1) 0.98
A roup. There was no severe malaria among patients >5years old.
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Figure 2. Parasite clearance and new clinical episodes of malaria in
patients with a positive malaria ﬁlm at baseline (AM = Argemone mexi-
cana group, ACT = Artemisinin Combination Therapy group). The ‘parasite
An exploratory analysis compared patients with and
without total parasite clearance at day 28 (irrespec-
tive of treatment group). We compared the incidence of
uncomplicated and severe malaria from days 29–84, and
0
200
400
600
800
1000
G
eo
m
et
ri
c 
m
ea
n
 p
ar
as
it
ae
m
ia
AM ( n=173)
ACT ( n=88)Incidence per patient of uncomplicated malaria (conﬁrmed)
Age-speciﬁc Incidence of severe malaria, in patients aged ≤5 years
Prevalence of moderate anaemia at day 84, n (%)
M: Argemone mexicana group; ACT: Artemisinin Combination Therapy g
atient) compared to thosewho had not (0.262 per patient,
= 0.011).
.7. Incidence of severe malaria, day 29–84
All cases of severe malaria occurred in children aged 4
ears or younger. We calculated the incidence for the age
roup ≤5 years: there were ﬁve episodes in 102 children
n the AM group (incidence 4.9% over 2 months) com-
ared to one in 52 children in the ACT group (1.9% over
months, P=0.37). In each group, 1.9% of patients had
oma/convulsions, and 1.9% in the AM group developed
evere anaemia (haematocrit <15%) requiring a transfu-
ion. One patient in the AM group had a second episode of
evere malaria with persistent vomiting (at day 49, follow-
ng treatment with i-m artemether for persistent vomiting
t d 14). One patient (a one year old girl) died suddenly at
ome following a convulsion at day 44, having previously
ade a good recovery after being given the second-line
reatment (As/Aq) at day 14. A thick ﬁlm taken on day 28
but analysed later) showed a parasitaemia of 2645/mcl,
t which time she was asymptomatic. She did not attend
gain before her death. It is probable that the fatal illness
as severe malaria 30 days after treatment with As/Aq.
.8. Anaemia
The prevalence of moderate anaemia (haematocrit
24%) was the same in both groups at d 84 (measured in
83/193 and 94/101 of the AM and ACT groups respec-
ively).
.9. Parasitaemia
In patients who were parasite positive at baseline
Figure 2), parasites had been cleared by day 7 in 22.6%
f the AM group and 77.5% in the ACT group (P<0.0001),
ut by day 28, only 17.9% and 50.0% remained clear
f parasites in each group respectively (P<0.0001). By
ay 84, the difference between the groups was further
educed (29.2% and 41.4% free of parasites in the AM and
CT groups respectively, P=0.05). In both groups geomet-
ic mean parasitaemia was markedly reduced compared
o the levels at baseline over the length of follow-up
below 200 parasites/mcl in both groups, see Figure 3),
nd there was no signiﬁcant difference in incidence of
linical episodes of malaria between the groups. In those
ho were parasite negative at baseline (Figure 4), 56%
n the AM group became parasitaemic by day 14, com-
ared to 7% in the ACT group (P=0.003) but by day 28,
0% and 57% were parasitaemic in the AM and ACT groups
espectively (P=0.49). Again there were no differencespositive’ lines show the percentage of patients who had parasites on thick
blood ﬁlms at the chosen timepoints. The ‘new clinical episodes’ lines
showthepercentageofpatientswhoexperiencedanewepisodeof clinical
malaria since the last scheduled follow-up visit.
in incidence of clinical episodes of malaria between the
groups.
3.10. The importance of parasite clearance9080706050403020100
Day of follow-up
Figure 3. Geometric mean parasitaemia for patients with a positive
malaria ﬁlm at baseline (AM = Argemone mexicana group, ACT =
Artemisinin Combination Therapy group).
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Figure 4. Parasite prevalence and new clinical episodes of malaria in
patients with a negative malaria ﬁlm at baseline. (AM = Argemone mexi-
cana group, ACT = Artemisinin Combination Therapy group). The ‘parasite
positive’ lines show the percentage of patients who had parasites on thick
blood ﬁlms at the chosen timepoints. The ‘new clinical episodes’ lines
showthepercentageofpatientswhoexperiencedanewepisodeof clinical
malaria since the last scheduled follow-up visit.
prevalence of moderate anaemia at day 84 (Table 3). There
was no statistically signiﬁcant difference in any outcome
between those with or without parasites on the day 28
thick ﬁlm, even after stratifying for age. There was a
non-signiﬁcant trend towards greater incidence of severe
malaria and greater prevalence of anaemia in those who
had no parasites at day 28. By logistic regression, the recur-
rence of malaria was found to be related to age (AOR 0.90
per added year of life, 95% CI 0.87–0.94) but not to treat-
ment group or day 28 parasitaemia (see Table 4).3.11. Adverse events
Most adverse effects were short-term and have been
discussed in detail elsewhere.7 Adverse events over the 84
Table 3
Outcome measures over months 2 and 3 (days 29–84) according to the presence
Parasites present at day
Incidence per patient of uncomplicated
malaria (conﬁrmed)
0.34 (68/201) [0.27–0.4
Age-speciﬁc incidence of severe malaria, in
patients aged ≤5 years
3/112 (2.7%) [0.6–7.6]
Prevalence of moderate anaemia at day 84, n
(%)
1/190 (0.5%) [0.0–2.9]
Table 4
Logistic regression model of factors inﬂuencing the recurrence of clinical episode
Variable Regression coefﬁcien
Treatment Group = AM (ref = ACT) 1.107
Sex = F (ref = M) 1.162
Age 0.897
Body temperature at day 29 0.734
Haematocrit at day 28 0.972
Parasitaemia at day 28 = 0 Ref
1–99 0.655
100–1999 0.682
2000–15000 1.246
>15000 1.334
AM: Argemone mexicana group; ACT: Artemisinin Combination Therapy group.ropical Medicine and Hygiene 105 (2011) 23–31
day follow-up were noted, but most were probably unre-
lated to the treatment (for example, otitis media, urinary
infections, sexually transmitted infections, malnutrition).
There were three serious adverse events in the course
of the follow-up, two deaths in the AM group and one
miscarriage in the ACT group. One of the deaths was prob-
ably due to severe malaria (see above). The other death
(an 18-month old boy who died at day 35) was proba-
bly due to septicaemia. His initial illness was successfully
treated on AM. At day 28 he complained of slight vomiting
and fever the previous night but his axillary temperature
was 35.5 ◦C and his thick ﬁlm was negative for malaria
parasites. His parents were advised to return if there was
any deterioration. At day 35, he returned seriously ill in a
coma (Blantyre score 1), with convulsions, jaundice, and
anuria for 24hours. His blood glucose was 3.9mmol/l, his
haematocrit was 25%, and on the thick ﬁlm there were
very few malaria parasites (41 per mcl), but numerous
neutrophils. He was given intramuscular artemether and
cefotaxime and referred urgently to hospital, but died
before arriving there. In view of the very low parasitaemia
and high neutrophilia, the fatal illness was most probably
septicaemia.
One miscarriage at about 13 weeks of gestation was
observed in awoman in the ACT group. At the start of treat-
ment shewas about 8weeks pregnant, andwasmistakenly
treated with As/Aq instead of SP. At day 35 after treatment
sheexperiencedamiscarriagewithprofusebleeding, need-
ing referral to hospital for evacuation of retained products
of conception.
3.12. Pregnant womenNineteenwomenwerepregnant at the start of the study,
13 in the AMgroup and six in the ACT group. Seven of these
hadnegative bloodﬁlms, and only three had >100parasites
per mcl at baseline. A further two women in the AM group
became pregnant during the course of follow-up. Twenty
of malaria parasites in a thick ﬁlm at day 28 [95% CI].
28 (n=201) Parasites absent at day 28 (n=87) P-value
1] 0.27 (23/86) [0.18–0.37] 0.46
3/38 (7.9%) [1.7–21.4] 0.33
2/81 (2.5%) [0.3–8.6] 0.36
s of malaria at days 29–84.
t 95% CI P-value
0.527–2.322 0.789
0.616–2.193 0.642
0.852–0.944 0.000
0.450–1.199 0.217
0.901–1.049 0.460
0.282–1.520 0.325
0.266–1.750 0.426
0.413–3.761 0.696
0.331–5.372 0.686
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f the 21 women were followed up seven months after the
tart of the study, ofwhom seven (35%)were still pregnant.
The babies resulting from the normal deliveries were
ll examined and found to be healthy. One miscarriage
as reported as a serious adverse event at day 35 after
reatment in the ACT group (see section on adverse events,
bove). Three miscarriages occurred in the AM group after
he end of the 84 d follow-up, two of them in women
ho only discovered their pregnancies at days 72 and 84,
o were not pregnant when they took AM. One stillbirth
ccurred ﬁve months after the treatment with AM.
.13. Need for re-treatment and cost
Between days 29–84, re-treatment with the ﬁrst-line
ntimalarial was needed at least once by 38.3% and 42.6%
f patients in theAMandACTgroups respectively (P=0.48).
ver the same period, at least one treatment with the
econd-line antimalarial was required by 10.9% in the AM
roup compared to 5.0% in the ACT group (P=0.08). Never-
heless 81% of patients in the AM group completed the 84
ay follow-upwithoutneeding treatmentwith anACT. This
ompares with all patients in the ACT group receiving the
rst line ACT, and a further 10% needing the second-line
CT. The average overall malaria-related treatment costs
ver the full 84 days of follow-up were 310 CFA Francs
FCFA) per patient in the AM group and 1338 FCFA per
atient in the ACT group (1 Euro = 655 FCFA; P<0.000001).
. Discussion
.1. Principal ﬁndings
Over all the 84 days of follow-up, there were no sig-
iﬁcant differences between the treatment groups in the
ncidence of uncomplicated malaria, severe malaria, mod-
rate anaemia, or serious adverse events. Exploratory
nalyses showed that, in this context of high malaria
ransmission, total parasite clearance at d 28 was not asso-
iatedwith a reduced incidence of uncomplicated or severe
alaria or of moderate anaemia over the subsequent two
onths. In the AM group 81% of patients completed the 84
ays of follow-up without needing treatment with an ACT,
nd the cost per patientwas a quarter of the cost in the ACT
roup.
.2. Strengths and weaknesses of the study
This is the ﬁrst study to our knowledge which exam-
nes whether total parasite clearance at day 28 is clinically
mportant in a context of high malaria transmission. The
andomisation worked well, as evidenced by the very sim-
lar baseline characteristics. We did not test for helminth
nfections which might have inﬂuenced some of the
utcome measures including treatment response and inci-
ence of anaemia. This is the largest randomised controlled
rial of any herbal remedy for malaria, with the longest
ollow-up, and the ﬁrst to include young children (who
re at greatest risk, and therefore in greatest need of treat-
ent).opical Medicine and Hygiene 105 (2011) 23–31 29
We kept samples of each batch of plant material for fur-
ther analysis, but at the time of the study the compound(s)
responsible for the antimalarial activity in vivo had not
been identiﬁed with certainty, so we could not standard-
ise according to levels of ‘active ingredients’. Nevertheless,
the plants were all harvested from the same area of Mali
so there was probably no great genetic or environmental
heterogeneity which could have affected the levels of phy-
tochemicals. Although we provided all patients with the
same amount of plant material and gave the same instruc-
tions on the preparation of the decoction, we were not able
to ensure that the preparation and dosage of the decoc-
tion was identical between patients and between episodes
for the same patient. In a previous study we did provide
a standard decoction (prepared by the traditional healer)
to all patients 6 but we felt that this would not be a prac-
tical public health intervention. In the present study we
improved thepracticalityof the interventionat theexpense
of a level of standardisation. If the herbal decoctionwere to
be used in public health programmes we felt it should be
sufﬁciently safe and effective in spite of a level of variability
in preparation and dosage which would occur in practice
outside of the research setting.
There isnouniversally acceptedmethod to conﬁrmtotal
parasite clearance. PCR would be the most sensitive but we
did not have the resources to do this. We counted a micro-
scopic examination as positive if at least one microscopist
had seen a single parasite. Thismethod is sensitive but runs
the risk of having some false positives (artefacts may occa-
sionally be mistaken for parasites). An alternative would
be to count a slide as positive only if both microscopists
saw at least one parasite. When we analysed the data using
this less sensitive deﬁnition, the difference in incidence of
uncomplicated malaria on d 29–84 between the parasite
positive and negative at day 28 became signiﬁcant (0.38 vs
0.25 per patient, P=0.02) but there was still no difference
in the incidence of severe malaria or anaemia. The abso-
lute parasitaemia had no effect on the risk of recurrence of
malaria in a logistic regression model, after adjusting for
age.
The difference in outcome between those who took AM
for one week and two weeks probably reﬂects underly-
ing differences in the disease and patient immune levels,
as patients were only advised to continue for >7 days if
they still had persisting mild symptoms. We cannot draw
any conclusions about the relative effectiveness of different
lengths of treatment as patients were not allocated ran-
domly to these. In the course of follow-up a small number
of patients in each group received treatments with possi-
ble antimalarial effects, some modern (such as doxycyline,
cotrimoxazole) and some traditional (such as Guiera sene-
galensis). However the proportion of patients taking these
was less than 10% and equal in each group. Those who
speciﬁcally tookanantimalarial notprescribedby the study
team were excluded from the analysis. Bednets were not
widely used at the time of the study, although after the
study ended we distributed bednets to all participants and
families in the villages.
Five patients of the 102 new episodes in the AM group
did not have a conﬁrmatory blood ﬁlm taken. If all of these
were positive with a parasitaemia >100/mcl, the incidence
iety of T30 M.L. Willcox et al. / Transactions of the Royal Soc
ofuncomplicatedmalaria in theAMgroupwouldhavebeen
68/193 = 0.35 per patient (instead of 0.33), but this still
wouldnothavebeen statistically signiﬁcant (P=0.61). If the
true difference in incidence of severe malaria between the
groups was 4.9% vs 1.9%, this study would not have sufﬁ-
cient power to detect it as statistically signiﬁcant. However
with our sample size, we can be 95% conﬁdent that the age-
speciﬁc incidenceof severemalariawould remainunder 6%
per month (over months 2–3) for children aged ≤5 years
treated with either AM or ACT, in similar conditions, which
is lower than in comparable studies of HMM (see section
on Meaning of the study, below).
The number of patients in this study was not large
enough to detect rare adverse events with any certainty,
and a larger study is needed in this regard. It would also
have been ideal to follow up all the pregnant women at
least to the end of their pregnancy.
4.3. Meaning of the study: possible explanations and
implications for clinicians and policymakers
The ﬁnding that parasite clearance did not inﬂuence
subsequent incidence of recurrent malaria or anaemia
may be surprising to some. It has often been argued that
residual or recurrent parasitaemia, even if asymptomatic,
would lead to more episodes of malaria and more anaemia.
Olliaro et al.11 found that recurrent asymptomatic par-
asitaemia (after initial clearance) progressed to fever in
42% of children, and argued that even asymptomatic recur-
rence of parasitaemia should be treated. Parasite clearance
maintained up to day 28 is the gold standard outcome
measure for antimalarial drug efﬁcacy trials.9,12 Yet the
clinical importance of total parasite clearance depends on
the epidemiological context. In a low-transmission area
where patients have little or no immunity, parasite clear-
ance is clearly the goal. However in high-transmission
areas where patients are semi-immune, and re-infection
happens rapidly, total parasite clearance may not be clini-
cally important.12 Asymptomatic parasitaemia (especially
multiclonal) may even be beneﬁcial in preventing clini-
cal attacks of malaria.13,14 This study is the ﬁrst to look at
the consequences of persisting asymptomatic parasitaemia
(rather than recurrence after initial clearance).
The most comparable study of HMM in a neighbour-
ing area of Burkina Faso8 found an incidence of ‘fever +
coma/convulsions’ of 5% per month for children receiving
chloroquine, and 11% per month for those not receiving it.
This is a narrower deﬁnition of severe malaria than ours
(which included persistent vomiting, respiratory distress
and severe anaemia). If we count only the cases of severe
malariawhichﬁt their deﬁnition, the incidence inour study
was lower (about 1% per month).
This suggests that both AM and As/Aq would be useful
treatments for the HMM. In a setting where resources are
limited, the relatively expensive ACTs could be reserved
for children under ﬁve years who are at greatest risk of
severe malaria and death, while AM could safely be used
for older patients. A health policy to use AM as ﬁrst line
for semi-immune patients, e.g. those >5 years old in a high
transmission area, may also help to reduce the spread of
resistance to ACTs. Wargo et al.15 have shown that theropical Medicine and Hygiene 105 (2011) 23–31
development of resistant strains might in fact be slower
when parasite clearance is not achieved: where subcura-
tive chemotherapy was administered, the resistant clone
was only partly released fromcompetitive suppression and
experienced a restriction in the size of its expansion after
treatment.
4.4. Unanswered questions and future research
Operational research is needed on strategies taking
advantage of the potential of AM. A ﬁrst step in such
research should be the analysis of batches of AM to be used,
inorder toverify that the content of knownanti-plasmodial
compounds is sufﬁcient. The plant contains at least three
alkaloids with strong in vitro activity against P. falciparum:
berberine, protopine and allocryptopine,16 but it remains
to be seen if these are also active in vivo. Once the sub-
stances responsible for the clinical activity of AMhave been
identiﬁed, a simple test needs to be developed to measure
their presence in various cultivars, and thus to control the
quality of different plant batches.
It is possible that if bednets were widely available and
used, the transmission of malaria might be reduced to
the point where parasite clearance might become relevant
to clinical outcomes. This would need to be evaluated in
future studies. Furthermorebetter outcomemeasures need
to be developed which distinguish between the issues of
Plasmodium infection and malarial disease in areas where
the prevalence of infection is high even among healthy
individuals. The ultimate aim of malaria treatment is to
prevent serious illness and death. In this regard more rele-
vant outcomemeasures are incidenceof severemalaria and
mortality. Larger sample sizes would be needed to demon-
strate relevant differences in these.
5. Conclusions
At the end of three months of follow-up in a high
transmission area there was no difference in incidence
of uncomplicated or severe malaria or anaemia between
patients treated ﬁrst-line with the locally produced AM
decoction and patients treated with As/Aq, or between
patients with and without total parasite clearance at day
28. The incidenceof severemalariawaskept toa lower level
than reported in other studies of HMM. If these ﬁndings
can be conﬁrmed, some antimalarials which are clinically
effective but do not produce parasite clearance could nev-
ertheless be appropriate in high transmission areas. Thus
AM could be tested operationally as ﬁrst-line treatment of
uncomplicated malaria in semi-immune patients (patients
>5 years old) in high transmission areas, and as ﬁrst aid
when modern antimalarials are not immediately acces-
sible. Such a policy could be tested as a way to delay
resistance to ACTs.
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